NCT07626216 Impact of rTMS on Abnormal Cortical fMRI in Patients With Dystonia
| NCT ID | NCT07626216 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Northwell Health |
| Condition | Dystonia Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-03-04 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2026-03-04 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
By tracking resting-state fMRI scans, we aim to discover how repetitive transcranial magnetic stimulation (rTMS) changes brain connectivity in individuals with dystonia.
Eligibility Criteria
Inclusion Criteria: * Male or female * 18 and 80 years of age. * Patients who manifest dystonia - sustained involuntary movement of the head, neck, trunk or limbs. * The dystonia may be spontaneous or genetic, specifically DYT1 or DYT6 and then only those patients who are demonstrating dystonia. The patient/subject will have a normal neurological exam except for dystonia. Exclusion Criteria: * Heredodegenrative dystonia of the type DYT8,9 or 10. * Past history of head trauma, stroke, epilepsy, demyelinating disease * Hypertension in excess of 160mmHg systolic and 90mmHg diastolic * Congestive heart failure * Diabetes * Past psychiatric conditions: e.g., depression * Systemic metabolic disease: e.g., Wilson's disease, progressive neurodegenerative disease (like supranuclear palsy or corticobasal ganglionic degeneration) * Magnetizable incorporated metal parts - like pacemakers * History or diagnosis of Parkinson's disease * Presence of myoclonus * No previous surgery for dystonia * Long term exposure to benzodiazepines, neuroleptics or anticonvulsants * No botulinum toxin within 12 weeks of baseline assessment and fMRI. * Moderate to severe cognitive impairment (judged by a minimental status of \<24.)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07626216 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Dystonia Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07626216 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07626216 currently recruiting?
Yes, NCT07626216 is actively recruiting participants. Contact the research team at cfernandez14@northwell.edu for enrollment information.
Where is the NCT07626216 trial being conducted?
This trial is being conducted at Manhasset, United States.
Who is sponsoring the NCT07626216 clinical trial?
NCT07626216 is sponsored by Northwell Health. The trial plans to enroll 10 participants.